Health Management

Despite heroic efforts by hospitals across the country, the healthcare supply chain has struggled in the fight against COVID-19.

Tagrisso, the targeted therapy made by AstraZeneca, could become the treatment of choice for the majority of lung cancer patients with mutations in a certain gene who are treated after surgery, based on findings presented this past weekend at the American Society of Clinical Oncology annual meeting.

During the American Society of Clinical Oncology 2020 Annual Meeting, Flatiron Health, Foundation Medicine, and Genentech will be presenting plans for the Prospective Clinico-Genomic study (PCG), a low-interventional pilot that will use a technology-enabled prospective data collection platform to simplify data collection for patients with lung cancer being treated through clinical trials. The idea is collect blood samples using Foundation Medicine’s liquid biopsy assay and analyze the results through Flatiron’s platform, to see if genomic changes can be detected over the course of cancer treatment. Bobby Green, MD, chief medical officer for Flatiron Health, spoke with Managed Healthcare Executive®.

Anna Lee, lead author of the abstract: Changes in Cancer Mortality Rates After the Adoption of the Affordable Care Act, discusses her study with MHE. Lee presented her study May 29 during ASCO 2020's virtual conference.

Sara Douglas, lead investigator of the Abstract: Video Conference Intervention for Distance Caregivers (DCGs) of Patients with Cancer: Improving Psychological Outcomes, discusses her study with MHE's Briana Contreras which will be presented at ASCO 2020.

A fresh look at MURANO data, released this week at the American Society of Clinical Oncology 2020 Annual meeting, shows the poor outcomes that result when patients halt treatment for good, and highlight the need to manage doses carefully to avoid toxicity.

The 2020 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1).

Healthcare providers have increasingly entered into value-based contracts with payers in recent years because they offer the opportunity to increase revenue-the primary driver of change for any business.

Cardinal Health Oncology survey shows oncologists want more training to care for growing number of cancer survivors.

As the world has gone virtual during the coronavirus pandemic, so has healthcare. Digital transformation has accelerated at warp speed, with virtual care delivery going from rare exception to operating norm almost overnight.

Concerned about neglected healthcare and spike in deaths, physicians’ public service nationwide campaign urges senior patients, “don’t neglect your health” in a video.

Dr. Charity provides mental health support and advice to the growing number of burned out health workers.

Physician Performance LLC’s Weekly Zoom Clinical Call fills physicians in about the initial steps of palliative care.

Doctor.com announced the launch of VirtualVisit - a new telemedicine solution that enables any provider to start practicing medicine virtually in less than 5 minutes, completely free of charge.

It’s difficult for people seeking mental health treatment to get it right now. COVID-19 has effectively halted most non-essential doctors’ visits and accessing behavioral health treatment is even more challenging than in the past due to limitations with residential treatment and outpatient group sessions.

Scheduling automation and optimization enables better patient experience, increases staff satisfaction, and improves workforce efficiency.

In today’s COVID-19 environment, care management has become more important than ever. Currently, about one in four Americans live with multiple chronic conditions, and when one considers that 80% of outcomes are determined by nonclinical factors, it’s an indisputable claim that people need help between healthcare encounters.

The opioid epidemic has led doctors and patients to look for other ways to control pain, and they’re turning to technology for answers.

He was reluctant to take the CEO job, but VanTrieste has the unique nonprofit drug manufacturer surpassing its goals and possibly branching out into the retail market.

As the coronavirus pandemic swept the U.S., state governments mandated dental offices open only for emergency procedures. But in the coming weeks, some dental practices may resume regular appointments in individual states where businesses considered “essential” are allowed to re-open.

COVID-19’s Impact on Health, Travel, Auto, Unemployment, Business, Restaurant, Special Events and Film/TV/Production Insurance, according to a report released by InsuranceQuotes.com.

Patients and their oncologists are weighing the pros and cons of delaying treatment. Once the outbreak subsides, how might the practice of oncology change?

A study of patients with inflammatory conditions who were prescribed biologic disease-modifying anti-rheumatic drugs had lower rates of chronic opioid use if they were adherent to their biologic therapy, according to new research.

Medical and dental care in the United States are like estranged colleagues: nominally on the same team but rarely, if ever, in touch with each other. Some value-based payment arrangements may start to mend the rift, which could both improve overall health and reduce healthcare costs.

FDA today approved Tecentriq (atezolizumab) as an initial treatment for adults with metastatic non-small cell lung cancer (NSCLC) for certain patients with high programmed-death ligand-1 (PD-L1) expression, marking the fifth approval of the immunotherapy in lung cancer and the fourth in advanced NSCLC.

The purpose of biosimilar is simple: reduce healthcare costs, pure and simple. Here are 11 trends affecting biosimilars over the last year in the U.S.

Residents and staff have been hit hard by the disease. PPE is in short supply. The deaths are taking an emotional toll on largely unheralded workers.

If American healthcare does wind up getting divided into pre- and post-COVID-19 eras, the migration from in-person visits to telehealth ones will likely be one of the biggest developments on the right-hand side of the inflection.

You have a highly trained, hardworking and fundamentally altruistic workforce. Don’t squander it.